<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03933631</url>
  </required_header>
  <id_info>
    <org_study_id>2018-9829</org_study_id>
    <nct_id>NCT03933631</nct_id>
  </id_info>
  <brief_title>Pilocarpine Use After Kahook Goniotomy</brief_title>
  <acronym>PAACK</acronym>
  <official_title>A Prospective Randomized Control Trial of Pilocarpine Use After Combined Cataract/Kahook Dual Blade Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to determine whether using pilocarpine provides added benefit to&#xD;
      the success of combined cataract + KDB surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glaucoma is the leading cause of irreversible blindness worldwide, and its treatment consists&#xD;
      of lowering intraocular pressure to prevent damage to the optic nerve and loss of vision[1].&#xD;
      Current methods for lowering intraocular pressure (IOP) include topical and oral medications,&#xD;
      laser trabeculoplasty, microincisional glaucoma surgery (MIGS), and traditional incisional&#xD;
      surgeries such as trabeculectomy and aqueous tube shunts. MIGS have become more popular in&#xD;
      recent years as less invasive methods than traditional surgeries that effectively reduce IOP&#xD;
      and help reduce the medication burden on patients[1]. There are multiple available MIGS&#xD;
      procedures, most of which act by increasing trabecular outflow. One such procedure is the&#xD;
      goniotomy via Kahook Dual Blade (KDB), which is usually performed in combination with&#xD;
      cataract surgery. KDB is an FDA approved device used to perform a goniotomy via an internal&#xD;
      approach. Strips of the nasal angle trabecular meshwork are removed providing a direct&#xD;
      pathway for aqueous outflow from the anterior chamber into the collector channels[2].&#xD;
&#xD;
      Pilocarpine, a parasympathomimetic agent, is a glaucoma medication that works by causing&#xD;
      contraction of the ciliary muscle leading to opening of the trabecular meshwork[3]. Due to&#xD;
      its frequent dosing requirement and large number of ocular and systemic side effects,&#xD;
      pilocarpine has largely fallen out of favor for the treatment of primary open angle glaucoma&#xD;
      (POAG), except in patients for whom few other alternatives exist. However, pilocarpine is&#xD;
      often used after goniotomy surgery. The rational for its use after goniotomy procedure is for&#xD;
      its miotic effect, which theoretically may prevent the formation of peripheral anterior&#xD;
      synechiae. Formation of peripheral anterior synechiae can lead to the closure of the cleft&#xD;
      that is generated and the possibility of failure of the procedure. While the theoretical&#xD;
      benefit of pilocarpine has been proposed, its actual benefit has never been proven. This&#xD;
      study will evaluate whether goniotomy via KDB / Cataract surgery without pilocarpine is&#xD;
      non-inferior to the same surgery procedure followed by treatment with pilocarpine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The &quot;Treatment Group&quot; will use 2% pilocarpine in the postoperative period in addition to standard postoperative drops (Prednisolone acetate and Ofloxacin). The &quot;Control Group&quot; will use only Prednisolone acetate and Ofloxacin, without pilocarpine.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with lowering of intraocular pressure (IOP)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The percentage of patients who had a reduction in IOP of 20% or more from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients whose regimen was reduced by 1 medication or more</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of progression towards further glaucoma surgeries</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">142</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Pilocarpine, Prednisolone acetate and Ofloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will use 2% pilocarpine in the postoperative period in addition to standard postoperative drops (Prednisolone acetate and Ofloxacin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone acetate and Ofloxacin (standard of care)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will use only Prednisolone acetate and Ofloxacin, without pilocarpine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pilocarpine</intervention_name>
    <description>pilocarpine hydrochloride ophthalmic solution 2% (20 mg/mL)</description>
    <arm_group_label>Pilocarpine, Prednisolone acetate and Ofloxacin</arm_group_label>
    <other_name>IsoptoÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Prednisolone acetate ophthalmic suspension 1%</description>
    <arm_group_label>Pilocarpine, Prednisolone acetate and Ofloxacin</arm_group_label>
    <arm_group_label>Prednisolone acetate and Ofloxacin (standard of care)</arm_group_label>
    <other_name>Pred Forte</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ofloxacin</intervention_name>
    <description>Ofloxacin Drops</description>
    <arm_group_label>Pilocarpine, Prednisolone acetate and Ofloxacin</arm_group_label>
    <arm_group_label>Prednisolone acetate and Ofloxacin (standard of care)</arm_group_label>
    <other_name>Ocuflox</other_name>
    <other_name>Floxin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with ocular hypertension or open angle glaucoma undergoing combined cataract&#xD;
             surgery with KDB&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with previous history of eye surgeries (including laser procedures)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen-Jeng (Melissa) Yao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Wakefield Campus</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10466</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 26, 2019</study_first_submitted>
  <study_first_submitted_qc>April 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2019</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Melissa Wen-Jeng Yao</investigator_full_name>
    <investigator_title>Professor of Ophthalmology and Visual Services</investigator_title>
  </responsible_party>
  <keyword>Cataract</keyword>
  <keyword>Glaucoma Surgery</keyword>
  <keyword>Vision</keyword>
  <keyword>Cataract Surgery</keyword>
  <keyword>Eye surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Pilocarpine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

